The Economics of Reproducibility in Preclinical Research.
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, r...
Main Authors: | Leonard P Freedman, Iain M Cockburn, Timothy S Simcoe |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-06-01
|
Series: | PLoS Biology |
Online Access: | http://europepmc.org/articles/PMC4461318?pdf=render |
Similar Items
-
Reproducibility in Preclinical in Vivo Research: Statistical Inferences
by: Charmaine J.M. Lim, et al.
Published: (2024-02-01) -
Is preclinical research in cancer biology reproducible enough?
by: Patrick Bodilly Kane, et al.
Published: (2021-12-01) -
Reproducible preclinical research-Is embracing variability the answer?
by: Natasha A Karp
Published: (2018-03-01) -
Recommendations for robust and reproducible preclinical research in personalised medicine
by: Vibeke Fosse, et al.
Published: (2023-01-01) -
Reproducibility of preclinical animal research improves with heterogeneity of study samples.
by: Bernhard Voelkl, et al.
Published: (2018-02-01)